4D Molecular Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 18, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 18, 2026
FDMT$12.48+1.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
(In thousands, except share and per share amounts)
| As of December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $60,241 | $149,336 |
| Marketable securities | 342,414 | 275,541 |
| Prepaid expenses and other current assets | 10,479 | 10,055 |
| Total current assets | 413,134 | 434,932 |
| Marketable securities, long-term | 111,379 | 80,583 |
| Property and equipment, net | 14,867 | 19,534 |
| Operating lease right-of-use assets, net | 18,143 | 21,074 |
| Other assets | 9,188 | 4,261 |
| Total assets | $566,711 | $560,384 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $11,159 | $4,386 |
| Accrued and other current liabilities | 26,874 | 18,869 |
| Deferred revenue | 360 | 257 |
| Operating lease liabilities, current portion | 5,592 | 5,637 |
| Total current liabilities | 43,985 | 29,149 |
| Deferred revenue, net of current portion | 745 | 1,057 |
| Derivative liability | 358 | 410 |
| Operating lease liabilities, long-term portion | 15,821 | 18,969 |
| Other liabilities | 138 | 193 |
| Total liabilities | 61,047 | 49,778 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized at December 31, 2025 and 2024; no shares issued and outstanding at December 31, 2025 and 2024 | — | — |
| Common stock, $0.0001 par value, 300,000,000 shares authorized at December 31, 2025 and 2024; 57,607,874 and 45,793,942 shares issued and outstanding at December 31, 2025 and 2024, respectively | 6 | 5 |
| Additional paid-in-capital | 1,221,235 | 1,086,567 |
| Accumulated other comprehensive gain | 727 | 229 |
| Accumulated deficit | (716,304) | (576,195) |
| Total stockholders’ equity | 505,664 | 510,606 |
| Total liabilities and stockholders’ equity | $566,711 | $560,384 |
The accompanying notes are an integral part of these financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.